Jiangsu Aidea Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Jiangsu Aidea Pharmaceutical has a total shareholder equity of CN¥1.2B and total debt of CN¥477.1M, which brings its debt-to-equity ratio to 41.4%. Its total assets and total liabilities are CN¥1.9B and CN¥775.7M respectively.
Key information
41.4%
Debt to equity ratio
CN¥477.11m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥472.37m |
| Equity | CN¥1.15b |
| Total liabilities | CN¥775.66m |
| Total assets | CN¥1.93b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 688488's short term assets (CN¥936.7M) exceed its short term liabilities (CN¥621.7M).
Long Term Liabilities: 688488's short term assets (CN¥936.7M) exceed its long term liabilities (CN¥154.0M).
Debt to Equity History and Analysis
Debt Level: 688488's net debt to equity ratio (0.4%) is considered satisfactory.
Reducing Debt: 688488's debt to equity ratio has increased from 22.7% to 41.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 688488 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 688488 has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 36.6% each year.